<DOC>
	<DOCNO>NCT00330148</DOCNO>
	<brief_summary>The treatment human African trypanosomiasis ( HAT ) meningoencephalitic phase relies two molecule officially register : melarsoprol , commonly use , poor safety profile become ineffective due parasite resistance ; eflornithine , good tolerance complicate expensive implement endemic country . nifurtimox , register Chagas ' disease use off-label since 1970 â€™ series case HAT , present available alternative . The limited number compound available , lack prospect development new product emergence resistance argument use therapeutic combination . This study evaluate efficacy safety three drug combination therapy : melarsoprol-nifurtimox , melarsoprol-eflornithine eflornithine-nifurtimox .</brief_summary>
	<brief_title>Randomized Clinical Trial Three Drug Combinations Late-Stage Gambiense Human African Trypanosomiasis</brief_title>
	<detailed_description>Dosages per drug either arm study : IV melarsoprol 1.8 mg/kg/day , daily 10 day ; IV eflornithine 400 mg/kg/day , 6-hourly 7 day ; oral nifurtimox 15 20 ( child &lt; 15 year ) mg/kg/day , 8-hourly 10 day . For efficacy assessment , patient followed-up 24 month treatment , plan clinical laboratory control . The safety assessment include clinical hematological adverse event .</detailed_description>
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<mesh_term>Melarsoprol</mesh_term>
	<mesh_term>Nifurtimox</mesh_term>
	<criteria>confirm secondstage T.b . gambiense infection : Infection diagnose parasitologically ( blood lymph node fluid ) white blood cell &gt; 5/mm3 cerebrospinal fluid ( CSF ) Trypanosomes detect CSF CSF cell count resident district write consent patient one parents/guardians child 15 year age . Trypanosome absent blood ( lymph node fluid ) CSF Or woman pregnant inclusion Or previous history HAT confirm treat last 24 month Or impossibility regular access treatment centre 2 year follow end treatment Or le 10 kg body weight Or refugee patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>trypanosomiasis</keyword>
	<keyword>gambiense</keyword>
	<keyword>combination drug therapy</keyword>
	<keyword>sleep sickness</keyword>
	<keyword>Uganda</keyword>
</DOC>